



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2018-19

Date: 13th August, 2018

To,

Department of Corporate Services

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

BSE CODE - 524348

BSE ID - AARTIDRUGS

National Stock Exchange of India Limited

"Exchange Plaza",

Bandra - Kurla Complex,

Bandra(E), Mumbai - 400 051

NSE CODE: AARTIDRUGS

Sub: Outcome of the Board Meeting held today i.e. 13th August, 2018 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors at its Meeting held today i.e. Monday, 13th August, 2018 had considered and approved the Audited Financial Results (Standalone & Consolidated) for the Quarter ended 30th June, 2018. Accordingly, please find enclosed herewith Statement of Audited Financial Results (Standalone & Consolidated) for the Quarter ended 30th June, 2018 along with the report of the Statutory Auditors.


The meeting commenced at 12:00 and concluded at 14:40 .

The above is for your kind information and records. You are requested to acknowledge the receipt.

Thanking you,

Yours faithfully,

For Aarti Drugs Limited



Vibhav S. Ranade

Company Secretary & Compliance Officer

ICSI M. No. A35284



Encl: A/A



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED									
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUN, 2018									
(Rs. in lakhs except for share data)									
Sr. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30th Jun 2018 (Audited)	31st Mar 2018 (Audited)	30th Jun 2017 (Audited)	31st Mar 2018 (Audited)	30th Jun 2018 (Audited)	31st Mar 2018 (Audited)	30th Jun 2017 (Audited)	31st Mar 2018 (Audited)
I	Revenue from operations	35,155	31,499	24,826	1,15,966	37,429	33,069	27,720	1,26,257
II	Other income	92	90	6	117	92	77	7	105
III	Total Income (I + II)	35,247	31,589	24,832	1,16,083	37,521	33,146	27,726	1,26,362
IV	Expenses :								
	(a) Cost of materials consumed	22,004	20,721	18,536	74,565	23,563	21,487	20,617	79,777
	(b) Purchase of stock-in-trade	636	670	824	2,597	941	924	1,137	3,976
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,213	(1,587)	(5,389)	(5,560)	891	(1,750)	(5,533)	(5,487)
	(d) Excise duty/taxes on goods sold	-	-	1,920	1,920	-	-	1,894	1,894
	(e) Employee benefits expense	1,300	1,328	1,189	5,049	1,485	1,506	1,360	5,794
	(f) Finance costs	883	851	846	3,301	941	893	894	3,496
	(g) Depreciation and amortisation expense	983	965	926	3,780	1,040	1,023	981	4,006
	(h) Other expenses	4,990	4,983	4,429	19,211	5,288	5,240	4,705	20,456
	Total expenses (IV)	32,008	27,931	23,280	1,04,862	34,149	29,324	26,054	1,13,911
V	Profit before exceptional items and tax (III - IV)	3,239	3,658	1,552	11,221	3,372	3,822	1,672	12,450
VI	Exceptional items	-	-	-	-	-	-	-	-
VII	Profit before tax (V - VI)	3,239	3,658	1,552	11,221	3,372	3,822	1,672	12,450
VIII	Tax Expenses :								
	Provision for taxation - Current	800	1,115	370	3,015	828	1,141	398	3,280
	- MAT credit entitlement	-	-	-	-	-	-	(4)	-
	- Earlier year	-	-	-	-	-	-	-	-
	Provision for deferred taxation	200	265	125	865	206	282	140	940
	Total tax expenses (VIII)	1,000	1,380	495	3,880	1,034	1,423	534	4,220
IX	Profit/(Loss) for the period from continuing operations (VII - VIII)	2,239	2,278	1,057	7,341	2,337	2,399	1,138	8,231
X	Profit / (Loss) from discontinuing operations	-	-	-	-	-	-	-	-
XI	Tax expenses of discontinuing operations	-	-	-	-	-	-	-	-
XII	Profit / (Loss) from discontinuing operations (X - XI)	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX - XII)	2,239	2,278	1,057	7,341	2,337	2,399	1,138	8,231
XIV	Other Comprehensive Income	-	(27)	-	(27)	-	(27)	-	(27)
XV	Total Comprehensive Income for the period (XIII+XIV)	2,239	2,251	1,057	7,314	2,337	2,372	1,138	8,204
XVI	Paid up equity share capital (face value of Rs.10 each)	2,358	2,358	2,386	2,358	2,358	2,358	2,386	2,358
XVI	Earning per equity share (in Rs.) (not annualised)								
	(1) Basic	9.40	9.46	4.43	30.67	9.82	9.97	4.77	34.41
	(2) Diluted	9.40	9.46	4.43	30.67	9.82	9.97	4.77	34.41

Notes :

- The above results for the quarter and period ended 30th June, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 13th August, 2018.
- Post the applicability of GST with effect from 1st July 2017, Sales are disclosed net of GST. Accordingly, Sales figures for the quarter ended 30th June 2018 are not comparable with the sales figures depicted in the results for the Quarter ended 30th June, 2017.
- Company has only one business segment i.e. pharmaceuticals.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

Place: Mumbai
Date: 13th August, 2018



For AARTI DRUGS LIMITED

Prakash M. Patil
Prakash M. Patil
(Chairman, Managing Director & CEO)

KIRTANE & PANDIT

Auditor's Report on Quarterly Standalone Financial Results and year to date Results of Aarti Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015

To,
**The Board of Directors of
Aarti Drugs Limited.**

We have audited accompanying Statement of Standalone financial results of **Aarti Drugs Limited** ("the Company") for the quarter ended June 30, 2018 ("the Statement"), being submitted by the Company to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These Standalone quarterly as well as year to date financial results have been prepared on the basis of interim financial statements, which are the responsibility the Company's Management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principals laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.


We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance as to whether the Statements are free of material misstatement. An audit includes examining, on a test basis, evidences supporting the amounts disclosed in financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.



In our opinion, and to the best of our information and according to the explanations given to us, these quarterly and year to date financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and;
- ii) give true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the Standalone profit and comprehensive income for the period and other financial information of the Company for the quarter ended June 30, 2018.

**For Kirtane & Pandit LLP,
Chartered Accountants,
FRN: 105215W/W100057**



Milind Bhave
Partner
M. No. 047973
Place: Mumbai
Date: 13/08/2018



Auditor's Report on Quarterly Consolidated Financial Results of Aarti Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements, 2015

To,
**Board of Directors,
Aarti Drugs Limited.**

We have audited accompanying Statement of Consolidated financial results of **Aarti Drugs Limited** ("the Company") and its subsidiaries (the Company and its subsidiaries together referred as "the Group") for the quarter ended June 30, 2018 ("the Statement"), being submitted by the Company to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of Company's Management and has been approved by the Board of Directors. The Company has been prepared in accordance with the recognition and measurement principals laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules and other recognized accounting practices and policies. Our responsibility is to express an opinion on the Statement based on our Audit of such interim Consolidated Financial Statements.

We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance as to whether the Statements are free of material misstatement. An audit includes examining, on a test basis, evidences supporting the amounts disclosed in financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.




We did not audit the Financial Statements of one subsidiary includes in the Quarterly Consolidated financial results, whose interim financial statements reflect total revenue as at quarter end of Rs 34,34,20,272/- These interim Financial Statements and other financial information have been audited by the other auditor whose report has been furnished to us, and our opinion on the quarterly financial results, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors.

In our opinion, and to the best of our information and according to the explanations given to us, the Statement

- i) includes the results of a subsidiary as given below :
 - a. Pinnacle Life Science Private Limited.
- ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and:
- iii) give true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the Consolidated profit and comprehensive income for the period and other financial information of the Group for the quarter ended June 30, 2018.

For Kirtane & Pandit LLP,
Chartered Accountants,
FRN: 105215W/W100057



Milind Bhave
Partner
M. No. 047973
Place: Mumbai
Date: 13/08/2018

